Skip to content

Clinical Study on the Safety and Effectiveness of Byquanneng High-Protein Compound Nutritional Powder for Nutritional Support for Cancer Chemotherapy Patients

Clinical Study on the Safety and Effectiveness of Byquanneng High-Protein Compound Nutritional Powder for Nutritional Support for Cancer Chemotherapy Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035125
Enrollment
Unknown
Registered
2020-08-01
Start date
2020-08-10
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumors of lung and digestive tract

Interventions

experimental group:Traditional diet and Byquanneng high-protein compound nutritional powder

Sponsors

Anshan Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-70 years old 2. Those whose swallowing functions well, who are conscious, have no communication difficulties, and can answer questions; 3. Those who meet the corresponding clinical diagnostic criteria for malignant tumors, and whose expected survival time is longer than 3 months (12 weeks); 4. Those who meet the trial product settings; 5. Those patients who need nutritional therapy,according to the researcher's judgment,; 6. Those who have not received chemotherapy in the past or had the last chemotherapy more than 12 months before and after assessment and chemotherapy can be performed at present, and the chemotherapy consent form should be signed; 7. Those who sign the informed consent voluntarily and participate in the research.

Exclusion criteria

Exclusion criteria: Those who have any of the following conditions are excluded from the trial: 1. Those with the following symptoms: gastrointestinal dysfunction, intestinal obstruction, liver or kidney failure; 2. Those who are allergic or intolerant to the ingredients of this product; 3. Long-term alcoholist, drug abuser or those who abuse drugs, which will affect the evaluation of test results; 4. Women who are pregnant or breastfeeding; 5. Those who the researcher thinks are not suitable to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
weight;Waist circumference;Grip strength;pace;

Countries

china

Contacts

Public ContactJian Liu

Department of Nutrition, Anshan Cancer Hospital

22706454@qq.com+86 18504126858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026